<DOC>
	<DOCNO>NCT02202837</DOCNO>
	<brief_summary>Defining Which Remission Criterion Month 6 Predicts Remission Month 12 Real Life Clinical Practice , Cohort Rheumatoid Arthritis Patients Treated Etanercept</brief_summary>
	<brief_title>Study With Etanercept Focusing Remission Predictability Remission Real Life Clinical Practice</brief_title>
	<detailed_description>The analysis primary endpoint base logistic regression define dependent variable remission Month 12 5 independent variable CDAI , SDAI , DAS28 , DAS28 Ultrasound , EULAR Boolean definition clinical practice clinical study . This analysis conduct arm study well pool patient group . In context seem reasonable ensure completion study total approximate number 100 patient ( approximately 50 patient per arm ) . In order ensure 50 completers arm , 70 patient recruited baseline , take account drop rate 30 % 1 year period .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Patients active RA start treatment etanercept accord prevail reimbursement criterion dose line SmPC . 1 . First cohort : Etanercept first biological product prescribe . 2 . Second cohort : Etanercept second biological product prescribe . 2 . Capable understanding willing provide sign dated write , voluntary inform consent protocolspecific procedure perform . 3 . Eighteen ( 18 ) year age old time consent . 1 . History current psychiatric illness would interfere subject 's ability comply protocol requirement give informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>